These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31689133)

  • 1. Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis.
    Reddy KP; Horsburgh CR; Wood R; Fields NF; Girouard MP; Costantini S; Hou T; Freedberg KA; Walensky RP
    Ann Am Thorac Soc; 2020 Feb; 17(2):202-211. PubMed ID: 31689133
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis.
    Uppal A; Rahman S; Campbell JR; Oxlade O; Menzies D
    PLoS Med; 2021 Sep; 18(9):e1003712. PubMed ID: 34520463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.
    Ryckman TS; Schumacher SG; Lienhardt C; Sweeney S; Dowdy DW; Mirzayev F; Kendall EA
    Lancet Glob Health; 2024 Jun; 12(6):e995-e1004. PubMed ID: 38762299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal.
    Losina E; Touré H; Uhler LM; Anglaret X; Paltiel AD; Balestre E; Walensky RP; Messou E; Weinstein MC; Dabis F; Freedberg KA; ;
    PLoS Med; 2009 Oct; 6(10):e1000173. PubMed ID: 19859538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis.
    Rose DN
    Ann Intern Med; 1998 Nov; 129(10):779-86. PubMed ID: 9841583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
    Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
    PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.
    Holmes CB; Zheng H; Martinson NA; Freedberg KA; Walensky RP
    Clin Infect Dis; 2006 Jun; 42(12):1772-80. PubMed ID: 16705586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
    Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB
    Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.
    Knight GM; Gomez GB; Dodd PJ; Dowdy D; Zwerling A; Wells WA; Cobelens F; Vassall A; White RG
    PLoS One; 2015; 10(12):e0145796. PubMed ID: 26717007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009-2016: survival model approach.
    Gezae KE; Abebe HT; Gebretsadik LG
    BMC Infect Dis; 2019 Feb; 19(1):107. PubMed ID: 30717705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.
    Gomez GB; Dowdy DW; Bastos ML; Zwerling A; Sweeney S; Foster N; Trajman A; Islam MA; Kapiga S; Sinanovic E; Knight GM; White RG; Wells WA; Cobelens FG; Vassall A
    BMC Infect Dis; 2016 Dec; 16(1):726. PubMed ID: 27905897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus.
    Reddy KP; Denkinger CM; Broger T; McCann NC; Gupta-Wright A; Kerkhoff AD; Pei PP; Shebl FM; Fielding KL; Nicol MP; Horsburgh CR; Meintjes G; Freedberg KA; Wood R; Walensky RP
    Clin Infect Dis; 2021 Oct; 73(7):e2077-e2085. PubMed ID: 33200169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya.
    van Gorkom J; Kibuga DK
    Tuber Lung Dis; 1996 Feb; 77(1):30-6. PubMed ID: 8733411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness and cost-effectiveness of community-based support for adolescents receiving antiretroviral treatment: an operational research study in South Africa.
    Fatti G; Jackson D; Goga AE; Shaikh N; Eley B; Nachega JB; Grimwood A
    J Int AIDS Soc; 2018 Feb; 21 Suppl 1(Suppl Suppl 1):. PubMed ID: 29485714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
    Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
    Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of novel first-line treatment regimens for tuberculosis.
    Owens JP; Fofana MO; Dowdy DW
    Int J Tuberc Lung Dis; 2013 May; 17(5):590-6. PubMed ID: 23575322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.
    Walensky RP; Ross EL; Kumarasamy N; Wood R; Noubary F; Paltiel AD; Nakamura YM; Godbole SV; Panchia R; Sanne I; Weinstein MC; Losina E; Mayer KH; Chen YQ; Wang L; McCauley M; Gamble T; Seage GR; Cohen MS; Freedberg KA
    N Engl J Med; 2013 Oct; 369(18):1715-25. PubMed ID: 24171517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India.
    Uhler LM; Kumarasamy N; Mayer KH; Saxena A; Losina E; Muniyandi M; Stoler AW; Lu Z; Walensky RP; Flanigan TP; Bender MA; Freedberg KA; Swaminathan S;
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20862279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.